Novomix 30 has been priced at Rs 525 with 300 units, which is a premixed analogue. Novorapid, on the other hand, is a rapid acting analogue and both will be available in the insulin delivery device - Flexpen.
Insulin analogues offer greater flexibility, higher efficacy and enhanced safety in the insulin regime, Novo Nordisk India managing director Sanjeev Shishoo said.
Commenting on the revenue targets for the products, Mr Shishoo said, We have not fixed any sales target, but we expect substantial growth in the next three to four years after the products are established.
He said that Novo Nordisks focus in India is purely on diabetes and majority of the Rs 170 crore revenues in India is likely to come from this segment only.
The Indian arm, a wholly-owned subsidiary of Denmark-based Novo Nordisk A/s, is committed to provide the best and most advanced therapy to people with diabetes in the country.
In India, Novo Nordisk has has more than 20 per cent market share in diabetes care and around 70 per cent market share in the insulin segment.
Insulin analogues are one of the major advances in insulin therapy in recent times and are genetically-engineered products in which human insulin molecules are modified, so as to enable safer and simpler insulin regimens.